Anastrozole Tablet
Product Images NDC 62135-490

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 62135-490). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Anastrozole Chemical Structure)

Chemical structure of Anastrozole, showing its molecular arrangement with a substituted benzene ring and a triazole group attached via a methylene bridge.*

FDA Label Image

Image Description (Anastrazole Tablets Figure 1)

A line chart comparing disease-free survival over time between anastrozole and tamoxifen treatments. The x-axis represents disease-free survival in months up to 90 months, and the y-axis represents the proportion of patients alive and disease-free. Two lines, dashed for anastrozole and solid for tamoxifen, show survival trends. Below the chart, a table lists the number of patients at risk at various time points for both treatments.*

FDA Label Image

Image Description (Anastrazole Tablets Figure 2)

A line graph comparing disease-free survival over months between two randomized treatments: anastrozole and tamoxifen. The y-axis shows the proportion alive and disease-free ranging from 0 to 1.0, while the x-axis shows disease-free survival time from 0 to 90 months. Both treatments show a decline in disease-free survival over time. Below the graph, the number of patients at risk for each treatment is presented at multiple time points.*

FDA Label Image

Image Description (Anastrazole Tablets Figure 3)

A Kaplan-Meier survival curve chart comparing the proportion event-free over time in months between Anastrozole and Tamoxifen treatments. The graph shows two lines representing each treatment, with a table below listing the number of patients at risk at various time points up to 120 months.*

FDA Label Image

Image Description (Anastrazole Tablets Figure 4)

A Kaplan-Meier survival curve chart comparing Anastrozole and Tamoxifen treatments over time measured in months up to 120 months. The y-axis shows the proportion of patients event-free, descending from 1.00 to 0.50. The chart includes a legend indicating Anastrozole as a solid line and Tamoxifen as a dashed line, with a table below showing the number of patients at risk at various time points for both treatments.*

FDA Label Image

Image Description (Anastrazole Tablets Figure 5)

A Kaplan-Meier curve comparing the proportion of patients with no progression of non-small cell lung cancer (NSCLC) over time (in months) between two randomized treatments: Anastrozole and Tamoxifen. The graph shows time to progression on the x-axis and proportion without progression on the y-axis, with data points and survival numbers listed at various months below the graph.*

FDA Label Image

Image Description (Anastrazole Tablets Figure 6)

A Kaplan-Meier survival plot illustrating the proportion of patients not progressing over time (in months) comparing two randomized treatments: Anastrozole (solid line) and Tamoxifen (dashed line). The x-axis represents time to progression in months, and the y-axis shows the proportion not progressing. Patient numbers at risk at various time points are listed below the graph.*

FDA Label Image

Image Description (Anastrozole Tablets Usp 30 Tablets)

Label for Anastrozole Tablets, USP 1 mg by Chartwell RX, LLC. The packaging shows a 30-count tablet bottle with prescription-only status. The label includes the NDC code 62135-490, dosage strength, and directions to see accompanying prescribing information. Manufacturer and storage information is also present, along with a barcode.*

FDA Label Image

Image Description (Anastrozole Tablets Usp 90 Tablets)

Anastrozole Tablets USP 1 mg oral tablets packaging label showing 90 tablets in the container. The label includes dosage strength of 1 mg, the prescription-only status (Rx only), and Chartwell RX, LLC as the labeler. It also displays NDC number 62135-490, storage instructions, manufacturing details, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.